Home > Healthcare > Biotechnology > Bioservices > Upstream Bioprocessing Market

Upstream Bioprocessing Market Share

Report ID: GMI8437
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Upstream Bioprocessing Market Share

The upstream bioprocessing industry is characterized by intense competition among key players, including biopharmaceutical companies, equipment manufacturers, contract manufacturing organizations (CMOs), and research institutions. Factors such as technological innovation, strategic partnerships, regulatory compliance, and geographic expansion drive competitiveness in this dynamic market.

Upstream Bioprocessing Market Companies

Key players operating in the upstream bioprocessing industry include:

Applikon Biotechnology
Boehringer Ingelheim GmbH
CellGenix GmbH
Corning, Inc.
Danaher Corporation (Cytvia)
Eppendorf AG
Merck KGaA
PBS Biotech, Inc.
Sartorius AG
Thermo Fisher Scientific Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The upstream bioprocessing market was valued at USD 9.5 billion in 2023 and is anticipated to record 9.7% CAGR over 2024-2032, owing to the increasing demand for biopharmaceuticals caused by high prevalence of chronic diseases.

The bioreactors/fermenters segment accounted for a share of 48.6% in market in 2023 and will grow significantly through 2032 as these vessels provide a controlled environment for the proliferation of cells or microorganisms, essential to produce biopharmaceuticals, enzymes, vaccines, and other bioproducts.

North America upstream bioprocessing industry is estimated to reach over USD 9.5 billion by 2032 attributed to the increasing collaboration & partnerships with an aim of improving awareness and education related to bioprocessing.

Applikon Biotechnology, Boehringer Ingelheim GmbH, CellGenix GmbH, Corning, Inc., Danaher Corporation (Cytvia), Eppendorf AG, Merck KGaA, PBS Biotech, Inc., Sartorius AG, and Thermo Fisher Scientific Inc.